Eye Lymphoma — Trials

Eye Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

72 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 3
Ph III recruiting: 1
Growth YoY: —
Industry share: 25%
Top sponsor: City of Hope Medical Center
Termination share: 30.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (14)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT01805037	Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas	terminated	Phase 1 / Phase 2	20	Northwestern UniversityOTHER	1	Sep 1, 2021	clinicaltrials
NCT01419795	Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant	terminated	Phase 2	3	Fred Hutchinson Cancer CenterOTHER	1